East India Pharmaceutical Works Limited Essentials
As of July 27, 2024, East India Pharmaceutical Works, Unlisted Shares are trading at ₹61.00 per share, with a 52-week high of ₹66 and 52-week low of ₹61. The minimun lot size is 3325 shares, and the shares are traded on NSDL and CDSL.
ISIN
INE254X01017
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Face Value
₹ 10
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total Share
66,74,858
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Total Income
₹ 233.35 undefined
Gross income refers to the total income earned by an individual on a pay check before taxes and other deductions. It comprises all incomes received by an individual from all sources – including wages, rental income, interest income, and dividends.
Profit After Tax
₹ ****
It is the final profit left over after subtracting all operating and non operating items from net revenue.
EPS
₹ ****
It is the profit allocated to each outstanding share of common stock.
P/E
****
It is a valuation parameter that measures the company's current share price relative to its per-share earnings. Generally, high P/E is Overvalued & low P/E is Undervalued.
P/B
****
It shows the relationship between the current price and the book value of each share. A lower P/B ratio can mean that the stock is undervalued.
Market Capitalisation
₹ 40.72 Cr
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
Enterprise Value
₹ ****
It measures companys total value, which includes market capitalization, debt and excludes cash.
Book Value
₹ 78.34
It calculates the per share value of a company based on its equity available to common shareholders
Intrinsic Value
₹ ****
Intrinsic value is the anticipated value of a company or stock determined through fundamental analysis. It is also referred to as the price a rational investor is willing to pay for an investment, given its level of risk.
Dividend Yield
2.05 %
It measures the amount of cash dividends distributed to equity shareholders relative to the market value per share.
Earnings Yield
4.15 %
Sector
Health Care
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Sub-sector
Pharmaceuticals
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category
Small Cap
Category is defined as a class or division of things regarded as having particular shared characteristics.
Cashflow - Operations
-₹ 3.11
It indicates the amount of money a company brings in from its ongoing and regular operations over a fixed period of time.
Cashflow - Financing
₹ 3.86
It shows the net flows of cash that are used to fund the company, which include transactions involving debt, equity, and dividends.
East India Pharmaceutical Works Limited Growth
Compounded Sales Growth
1 Year
3 Year
6 Year
Compounded Profit Growth
1 Year
4 Year
6 Year
Return On Equity
2018
2021
2023
Highlights
First-of-their-kind Generic Drugs - East India Pharmaceutical Works developed several first-of-its-kind generic drugs in India, including the first indigenously developed antimalarial drug, the first generic version of metformin (anti-diabetic), and the first generic version of ramipril (anti-hypertensive). The company also has a strong pipeline of new products in development across various therapeutic areas.
Revenue Growth - The company's revenue has experienced a substantial rise, climbing from ₹201.6 Cr in FY22 to ₹233.3 Cr in FY23, indicating a growth rate of 15.7%. Over the past five years, the company's revenue has consistently increased, achieving a compound annual growth rate (CAGR) of 9.03% from FY18 to FY23.
Profitability -The company's profitability has consistently lagged behind industry standards. The EBIT margin, which stood at 3.6% in FY18, decreased to 2.9% in FY23, reflecting a Compound Annual Growth Rate (CAGR) of -4.65%. Although the net profit margin slightly increased from 0.4% in FY18 to 0.7% in FY23, the overall profitability was notably affected in FY23. This decline can be attributed to the rise in operating and other costs, impacting the overall profitability of the business.
Investment Thesis - When comparing East India Pharmaceutical Works to industry peers, the average price-to-earnings (P/E) ratio is around 32.17x. After incorporating the respective discounts, the share price is estimated to be in the range of ₹57 to ₹61. Despite positive signals related to revenue growth and profitability, the company seems to be slightly overvalued. Additionally, the Indian Pharmaceutical Industry is dominated by established giants serving a similar target market, limiting potential opportunities for East India Pharmaceutical Works to thrive.